Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs

Bain Previously Provided Up To $300m

 
• By Mandy Jackson

The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.

3D illustration of a human heart presented in geometric shapes consisting of white lines scattered around its periphery
Cardurion's series B also will fund drug discovery and business development • Source: Shutterstock

More from Financing

More from Business